Yazar "Giden, Asli Odabasi" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    International Forum: The Turkish perspective on apheresis activity: The Turkish apheresis registry report
    (Pergamon-Elsevier Science Ltd, 2023) Ozatli, Duzgun; Giden, Asli Odabasi; Erkurt, Mehmet Ali; Korkmaz, Serdal; Basci, Semih; Ulas, Turgay; Turgut, Burhan
    Therapeutic apheresis is an extracorporeal treatment that selectively removes abnormal cells or harmful sub-stances in the blood that are associated with or cause certain diseases. During the last decades the application of therapeutic apheresis has expanded to a broad spectrum of hematological and non-hematological diseases due to various studies on the clinical efficacy of this procedure. In this context there are more than 30 centers per-forming therapeutic apheresis and registered in the apheresis database in Turkey. Herein, we, The Turkish Apheresis Registry, aimed to analyze some key articles published so far from Turkey regarding the use of apheresis for various indications.
  • Küçük Resim Yok
    Öğe
    Real-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey
    (Taylor & Francis Ltd, 2023) Bakirtas, Mehmet; Dal, Mehmet Sinan; Yigenoglu, Tugce Nur; Giden, Asli Odabasi; Serin, Istemi; Basci, Semih; Kalpakci, Yasin
    A multicenter, retrospective, observational study was conducted to explore effectiveness and safety of ixazomib plus lenalidomide with dexamethasone (IRd) in relapsed/refractory multiple myeloma (RRMM) patients following at least >= two lines of therapy. Patients' treatment responses, overall response rate, progression-free survival rate, and adverse events were recorded. Mean age of 54 patients was 66.5 +/- 9.1 years. There were 20 patients (37.0%) with progression. Median progression-free survival was 13 months in patients who received a median of three therapy lines in a 7.5-month follow-up period. Overall response rate was 38.5%. Of 54 patients, 19 (40.4%) had at least one adverse event, and nine (19.1%) had an adverse event of at least grade 3 or more. Of 72 adverse events observed in 47 patients, 68% were grade 1 or 2. Treatment was not stopped in any patient due to adverse events. IRd combination therapy was effective and safe in heavily treated RRMM patients.